AU2003259358A1 - Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use - Google Patents

Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Info

Publication number
AU2003259358A1
AU2003259358A1 AU2003259358A AU2003259358A AU2003259358A1 AU 2003259358 A1 AU2003259358 A1 AU 2003259358A1 AU 2003259358 A AU2003259358 A AU 2003259358A AU 2003259358 A AU2003259358 A AU 2003259358A AU 2003259358 A1 AU2003259358 A1 AU 2003259358A1
Authority
AU
Australia
Prior art keywords
immunogenic composition
therapeutic use
cell epitopes
epitopes
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259358A
Other languages
English (en)
Other versions
AU2003259358A8 (en
Inventor
Claire Ashman
Jonathan Henry Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220212A external-priority patent/GB0220212D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003259358A1 publication Critical patent/AU2003259358A1/en
Publication of AU2003259358A8 publication Critical patent/AU2003259358A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003259358A 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use Abandoned AU2003259358A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0220212.5 2002-08-30
GB0220212A GB0220212D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
GB0304672.9 2003-02-28
PCT/GB2003/003703 WO2004019974A2 (en) 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Publications (2)

Publication Number Publication Date
AU2003259358A1 true AU2003259358A1 (en) 2004-03-19
AU2003259358A8 AU2003259358A8 (en) 2004-03-19

Family

ID=31980003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259358A Abandoned AU2003259358A1 (en) 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Country Status (8)

Country Link
US (1) US20060147417A1 (enExample)
EP (1) EP1532172A2 (enExample)
JP (1) JP2006503017A (enExample)
AR (1) AR041086A1 (enExample)
AU (1) AU2003259358A1 (enExample)
CA (1) CA2496409A1 (enExample)
TW (1) TW200407162A (enExample)
WO (1) WO2004019974A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
US20110002955A1 (en) * 2006-09-25 2011-01-06 Sj Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
US20160166637A1 (en) * 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
KR20210110842A (ko) 2018-12-28 2021-09-09 유나이티드 바이오메디칼 인크. 인터루킨 6(il-6)을 표적화하는 펩타이드 면역원 및 il-6 조절장애에 의해 영향을 받는 질환의 면역요법을 위한 이의 제형
AU2022212600A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance
JP2024531390A (ja) * 2021-08-20 2024-08-29 ネオヴァクス ＩＬ－４および／またはＩＬ－１３ＲＮＡを含むｍＲＮＡワクチンおよびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
WO2000065058A1 (en) * 1999-04-23 2000-11-02 Pharmexa A/S Method for down-regulating il5 activity
AU1599301A (en) * 1999-11-11 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens

Also Published As

Publication number Publication date
US20060147417A1 (en) 2006-07-06
CA2496409A1 (en) 2004-03-11
JP2006503017A (ja) 2006-01-26
EP1532172A2 (en) 2005-05-25
WO2004019974A2 (en) 2004-03-11
TW200407162A (en) 2004-05-16
WO2004019974A3 (en) 2004-07-22
AR041086A1 (es) 2005-04-27
AU2003259358A8 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
GB0212885D0 (en) Therapeutic epitopes and uses thereof
AU2003259358A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
IL201916A (en) Stem cells from human placenta, their characteristics, preparation and use
AU2003221683A1 (en) Thermal interface materials and methods for their preparation and use
AU2003248721A1 (en) Adsorbents, methods of preparation, and methods of use thereof
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
IL178432A0 (en) Human glp-1 mimetibodies, compositions, methods and uses
AU2003243984A1 (en) Hydrogenated copolymer and composition thereof
AU2003237788A1 (en) Electrode constructs, and related cells and methods
AU2003239614A1 (en) Cardiolipin compositions, methods of preparation and use
TWI319400B (en) Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application
DE60237654D1 (de) Komplexes Lithium-Mangan-Oxid, dessen Herstellung und Verwendung
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
AU2003246130A8 (en) Heat-storage material, composition therefor, and uses of these
AU2003259374A1 (en) Vaccine comprising il-13 and an adjuvant
PL371382A1 (en) Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
AU2003292751A1 (en) Hair care composition
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
GB2409796B (en) Composition comprising proteinaceous material, its preparation and use
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
GB0317376D0 (en) Immunogenic protein and uses thereof
AU2002315931A1 (en) Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use
AU2003231343A1 (en) Resistin binding proteins, their preparation and use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase